N-[(E)-[4,5-bis(1,3-benzodioxol-5-yl)-3-nitro-2-furyl]methyleneamino]aniline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: N-[(E)-[4,5-bis(1,3-benzodioxol-5-yl)-3-nitro-2-furyl]methyleneamino]aniline
• 英文别名: N-[(E)-[4,5-bis(1,3-benzodioxol-5-yl)-3-nitrofuran-2-yl]methylideneamino]aniline
• 化学式: C25H17N3O7
• 分子量: 471.4
• InChiKey: KGUAPQNIHXQLAW-RPPGKUMJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.7
• 重原子数：
  35
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  120
• 氢给体数：
  1
• 氢受体数：
  9

文献信息

• ONCOSTATIN M (OSM) ANTAGONISTS FOR PREVENTING CANCER METASTASIS AND IL-6 RELATED DISORDERS
  申请人：Jorcyk Cheryl

  公开号：US20150093391A1

  公开（公告）日：2015-04-02

  A method of treating cancer or metastasis is provided involving administering at least one oncostatin M (OSM) antagonist to a subject, wherein the subject has been diagnosed with cancer. Administration of an OSM antagonist such as a small molecule pharmaceutical is provided as well as an anti-OSM antibody, an anti-OSM aptamer, and an OSM mRNA antagonist. The OSM antagonists were found to inhibit or prevent tumor cell detachment, proliferation and metastasis in several cancer types.
• PHARMACEUTICAL COMPOSITIONS COMPRISING ONCOSTATIN M (OSM) ANTAGONIST DERIVATIVES AND METHODS OF USE
  申请人：Boise State University

  公开号：US20200323960A1

  公开（公告）日：2020-10-15

  A method of treating cancer or metastasis is provided involving administering at least one oncostatin M (OSM) antagonist to a subject, wherein the subject has been diagnosed with cancer. Administration of an OSM antagonist such as a small molecule pharmaceutical is provided as well as an anti-OSM antibody, an anti-OSM aptamer, and an OSM mRNA antagonist. The OSM antagonists were found to inhibit or prevent tumor cell detachment, progression, proliferation and metastasis in several cancer types.
• US9550828B2
  申请人：——

  公开号：US9550828B2

  公开（公告）日：2017-01-24